# High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

> **NCT03007823** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 20 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** High-activity natural killer

## Key facts

- **NCT ID:** NCT03007823
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2017-12-01
- **Final completion:** 2019-06-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03007823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03007823, "High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03007823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*